Dr. John Cush RheumNow
5 years 3 months ago
French Vasculitis registry studied 354 GPA patients- 25% had hypereosinophilia (HE) ≥ 500; mostly male (73%) w/ most skin dz (49%) peripheral neuropathy (32%) & higher BVAS (21 vs 18, p= 0.01): severe HE had more baseline renal dysfunction https://t.co/G4s3CEavL9
With the expansion of knowledge regarding the safety of newer agents in pregnancy comes the PreCARA study showing that when pregnancy is planned and patients with rheumatoid arthritis (RA) are treated with a modified treat-to-target (T2T) approach, superior outcomes can be anticipated.
Dr. John Cush RheumNow
5 years 3 months ago
Enthesitis is a tricky and unclear topic. Dr. Robert Chao ( @doctorRBC ) shares #EULAR2021 learnings.
https://t.co/pZRMZtbJAh https://t.co/kQEKveZFnY
Dr. John Cush RheumNow
5 years 3 months ago
What do Rheumatologists Know about XLH? Here's a four question Survey for Rheumatologists on a rare disorder - https://t.co/TuY1fXAAk5
Dr. John Cush RheumNow
5 years 3 months ago
FINCH 1 Trial Filgotinib in Rheumatoid Arthritis
The Annals of Rheumatic Disease has published the results of a head-to-head trial showing that the JAK1 preferential inhibitor filgotinib was superior to adalimumab in active RA on MTX.
https://t.co/d501qhArfP https://t.co/YGH5LQDGbs
Dr. John Cush RheumNow
5 years 3 months ago
Mouse model of psoriasis; 10 week exposure of western diet (high sugar & fat) induced dysbiosis and increased skin psoriasis & PsA , with increased IL-17A γδ T cells and helper type 17 cytokines. Treatment w/ Abx reduced IL-23 mediated dz. https://t.co/fTCnYiQ3wL
The question of whether psoriasis is a state or pre-clinical psoriatic arthritis has been addressed by several studies; with one suggesting that biologic use in psoriasis may aver the future development of psoratic arthritis (PsA).
The Annals of Rheumatic Disease has published the results of a head-to-head trial showing that the Janus kinase-1 (JAK1) preferential inhibitor filgotinib was superior to a tumour necrosis factor-α inhibitor (adalimumab) in active rheumatoid arthritis (RA) on methotrexate (MTX).
Dr. John Cush RheumNow
5 years 3 months ago
Can Focus Score Predict Risk of Lymphoma in Sjogren's Patients?
https://t.co/kBptqUx2XG https://t.co/8y1736Kj8T
Dr. John Cush RheumNow
5 years 3 months ago
RheumNow survey question for Rheumatologists - A man with osteoporosis and recurrent fractures should be tested for: phosphorous, testosterone, magnesium or HLA-B27; answer here> https://t.co/TuY1fXAAk5
Dr. John Cush RheumNow
5 years 3 months ago
Do gender and racial disparities play a role in PsA patients?
https://t.co/SrMcGOIbu4 https://t.co/QKD0VoK6fC
Dr. John Cush RheumNow
5 years 3 months ago
What Does Limited Scleroderma with ScL70 Look Like?
https://t.co/nlsSiO83Bz https://t.co/idPlQSPhRn
Dr. John Cush RheumNow
5 years 3 months ago
What are some predictors of PSA development in psoriasis patients?
https://t.co/cPlTEJBK5U https://t.co/il6ajaVvtq
Dr. John Cush RheumNow
5 years 3 months ago
Which patients with psoriasis are at risk to develop PsA?
The potential transition from psoriasis (PsO) to psoriatic arthritis (PsA) has not been a strong focus for several years but is gaining momentum.
https://t.co/5sj5HSnke3 https://t.co/UhRHXQwZfG
